Ensign Peak Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $899K | Sell |
41,700
-18,750
| -31% | -$404K | ﹤0.01% | 1302 |
|
|
2025
Q1 | $1M | Hold |
60,450
| – | – | ﹤0.01% | 1243 |
|
|
2024
Q4 | $1.11M | Hold |
60,450
| – | – | ﹤0.01% | 1256 |
|
|
2024
Q3 | $930K | Hold |
60,450
| – | – | ﹤0.01% | 1364 |
|
|
2024
Q2 | $982K | Hold |
60,450
| – | – | ﹤0.01% | 1288 |
|
|
2024
Q1 | $1.12M | Sell |
60,450
-3,050
| -5% | -$56.4K | ﹤0.01% | 1242 |
|
|
2023
Q4 | $1.99M | Hold |
63,500
| – | – | ﹤0.01% | 917 |
|
|
2023
Q3 | $1.32M | Hold |
63,500
| – | – | ﹤0.01% | 1002 |
|
|
2023
Q2 | $1.52M | Hold |
63,500
| – | – | ﹤0.01% | 979 |
|
|
2023
Q1 | $1.2M | Hold |
63,500
| – | – | ﹤0.01% | 1096 |
|
|
2022
Q4 | $1.01M | Buy |
63,500
+23,500
| +59% | +$374K | ﹤0.01% | 1154 |
|
|
2022
Q3 | $654K | Sell |
40,000
-101,470
| -72% | -$1.66M | ﹤0.01% | 1320 |
|
|
2022
Q2 | $1.99M | Buy |
141,470
+101,470
| +254% | +$1.43M | ﹤0.01% | 803 |
|
|
2022
Q1 | $969K | Buy |
40,000
+10,220
| +34% | +$248K | ﹤0.01% | 1226 |
|
|
2021
Q4 | $695K | Buy |
+29,780
| New | +$695K | ﹤0.01% | 1468 |
|
|
2021
Q2 | – | Sell |
-59,702
| Closed | -$1.54M | – | 1822 |
|
|
2021
Q1 | $1.54M | Sell |
59,702
-61,137
| -51% | -$1.58M | ﹤0.01% | 1233 |
|
|
2020
Q4 | $6.46M | Sell |
120,839
-5,439
| -4% | -$291K | 0.01% | 527 |
|
|
2020
Q3 | $5.21M | Buy |
126,278
+109,515
| +653% | +$4.52M | 0.01% | 618 |
|
|
2020
Q2 | $813K | Buy |
16,763
+2,470
| +17% | +$120K | ﹤0.01% | 1340 |
|
|
2020
Q1 | $604K | Buy |
+14,293
| New | +$604K | ﹤0.01% | 1342 |
|